Immediate Impact
63 standout
Citing Papers
A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy
2025 Standout
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Works of Stacy L. Throm being referenced
MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport
2011
Whole-Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration
2010
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Stacy L. Throm | 185 | 227 | 53 | 83 | 19 | 426 | |
| Stefanie Reif | 104 | 181 | 83 | 44 | 22 | 433 | |
| W Scheef | 102 | 139 | 31 | 20 | 22 | 401 | |
| Theresa Dunn | 192 | 145 | 13 | 19 | 14 | 415 | |
| S Matthes | 54 | 205 | 31 | 22 | 16 | 377 | |
| A. Hagey | 258 | 154 | 20 | 20 | 26 | 471 | |
| J. P. Eder | 140 | 145 | 49 | 23 | 20 | 412 | |
| M. Lind | 94 | 240 | 68 | 30 | 20 | 478 | |
| Rai‐Hua Lai | 173 | 252 | 84 | 15 | 17 | 498 | |
| Joanna M. Lubieniecka | 268 | 132 | 18 | 20 | 22 | 506 | |
| Colin Phipps | 172 | 141 | 26 | 22 | 19 | 403 |
All Works
Loading papers...